CA
NZ
UK
AU
IND
US
…
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
MiMedx Group Inc develops and markets human placental-derived regenerative biologic products used in wound care and surgical applications. Long-term growth may be supported by aging populations, rising prevalence of chronic wounds and broader adoption of regenerative therapies; investors may find the company attractive for its procedure-driven allograft portfolio and a direct sales and distribution footprint.
The most important investment risk is regulatory, legal and reimbursement uncertainty linked to prior accounting and governance problems, which could constrain revenue recognition, market access and management focus.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 66.26M | 57.29M | 30.63M | -29.99M | -10.04M |
| Net income | 48.58M | 42.42M | 67.44M | -30.20M | -10.29M |
| Selling general administrative | 266.19M | 225.09M | 206.72M | 208.79M | 198.36M |
| Gross profit | 345.62M | 288.81M | 266.84M | 219.53M | 215.33M |
| Reconciled depreciation | 14.88M | 6.04M | 3.60M | 4.05M | 5.18M |
| Ebit | 68.05M | 59.31M | 37.09M | -24.97M | -5.00M |
| Ebitda | 82.93M | 65.35M | 40.52M | -20.93M | 0.18M |
| Depreciation and amortization | 14.88M | 6.04M | 3.43M | 4.04M | 5.18M |
| Non operating income net other | - | - | - | - | -0.02M |
| Operating income | 63.89M | 58.87M | 37.12M | -24.97M | -5.00M |
| Other operating expenses | 354.74M | 290.01M | 284.36M | 292.81M | 263.60M |
| Interest expense | 1.78M | 1.01M | 6.46M | 5.02M | 4.98M |
| Tax provision | 17.68M | 15.30M | 0.60M | 0.21M | 0.25M |
| Net interest income | 2.93M | -1.01M | -6.31M | -5.02M | -4.98M |
| Non recurring | - | - | - | - | 0.05M |
| Income tax expense | 17.68M | 15.30M | -36.81M | 0.21M | 0.25M |
| Total revenue | 418.63M | 348.88M | 321.48M | 267.84M | 258.62M |
| Total operating expenses | 281.29M | 229.94M | 229.73M | 244.50M | 220.31M |
| Cost of revenue | 73.01M | 60.07M | 54.63M | 48.32M | 43.28M |
| Total other income expense net | 2.38M | -1.57M | -6.48M | -5.02M | -5.03M |
| Net income from continuing ops | 48.58M | 42.00M | 4.34M | -30.20M | -10.29M |
| Net income applicable to common shares | - | - | - | -36.78M | -10.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 342.65M | 263.92M | 239.05M | 171.43M | 187.93M |
| Intangible assets | 14.16M | 11.63M | 5.26M | 5.85M | 5.38M |
| Other current assets | 10.30M | 7.83M | 1.75M | 2.63M | 2.81M |
| Total liab | 86.11M | 70.81M | 96.33M | 189.42M | 187.85M |
| Total stockholder equity | 256.55M | 193.11M | 142.72M | -17.99M | 0.08M |
| Other current liab | 46.92M | 35.88M | 36.96M | 34.71M | 34.97M |
| Common stock | 0.15M | 0.15M | 0.15M | 0.11M | 0.11M |
| Capital stock | 0.15M | 0.15M | 0.15M | 0.11M | 92.61M |
| Retained earnings | -42.68M | -91.26M | -133.68M | -17.99M | -161.71M |
| Other liab | - | - | - | 2.33M | 4.87M |
| Good will | 19.44M | 19.44M | 19.44M | 19.98M | 19.98M |
| Other assets | - | - | - | 0.15M | 0.19M |
| Cash | 166.12M | 104.42M | 82.00M | 65.95M | 87.08M |
| Total current liabilities | 64.27M | 45.59M | 46.01M | 43.56M | 42.36M |
| Current deferred revenue | - | - | -1.55M | - | - |
| Net debt | -143.59M | -79.57M | -33.90M | -17.36M | -38.96M |
| Short term debt | 2.82M | 2.31M | 1.55M | - | - |
| Short long term debt | 1.50M | 1.00M | - | - | - |
| Short long term debt total | 22.53M | 24.84M | 48.10M | 48.59M | 48.13M |
| Other stockholder equity | 299.08M | 284.22M | 276.25M | -92.61M | 161.68M |
| Property plant equipment | - | - | - | 11.26M | 13.86M |
| Total current assets | 277.47M | 191.89M | 164.26M | 134.20M | 148.52M |
| Net tangible assets | - | - | - | -43.82M | -25.28M |
| Net receivables | 75.71M | 55.83M | 53.87M | 43.79M | 41.10M |
| Long term debt | 16.47M | 17.83M | 48.10M | 48.59M | 48.13M |
| Inventory | 25.34M | 23.81M | 21.02M | 13.18M | 11.39M |
| Accounts payable | 14.53M | 7.41M | 9.05M | 8.85M | 7.38M |
| Accumulated other comprehensive income | - | - | -239.05M | - | -92.49M |
| Common stock total equity | - | - | - | - | 0.11M |
| Retained earnings total equity | - | - | - | - | -161.71M |
| Treasury stock | - | - | - | - | -4.02M |
| Non currrent assets other | 7.27M | 1.11M | 0.20M | 0.15M | 0.19M |
| Non current assets total | 65.18M | 72.03M | 74.79M | 37.23M | 39.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -9.58M | -3.38M | -2.66M | -3.40M |
| Change to liabilities | - | - | - | 1.05M | -0.33M |
| Total cashflows from investing activities | -6.89M | -9.58M | -2.15M | -2.66M | -3.40M |
| Net borrowings | -1.00M | -31.72M | 0.00M | -0.04M | -0.04M |
| Total cash from financing activities | -5.41M | -34.20M | -8.57M | -0.58M | -3.35M |
| Change to operating activities | - | - | - | -2.78M | -17.09M |
| Net income | 48.58M | 42.00M | 67.44M | -30.20M | -10.29M |
| Change in cash | 61.70M | 22.42M | 16.05M | -21.13M | -8.73M |
| Begin period cash flow | 104.42M | 82.00M | 65.95M | 87.08M | 95.81M |
| End period cash flow | 166.12M | 104.42M | 82.00M | 65.95M | 87.08M |
| Total cash from operating activities | 74.00M | 66.20M | 26.77M | -17.89M | -1.98M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 14.88M | 6.04M | 3.43M | 4.05M | 5.18M |
| Other cashflows from investing activities | -2.09M | -0.04M | -0.17M | - | 0.07M |
| Dividends paid | - | - | 1.00M | -0.65M | - |
| Change to inventory | -1.53M | -2.36M | -7.84M | -1.79M | -1.03M |
| Change to account receivables | -26.39M | -2.55M | -12.24M | -5.55M | -4.93M |
| Sale purchase of stock | -3.12M | -2.64M | -9.52M | -1.19M | -4.75M |
| Other cashflows from financing activities | -1.29M | -1.24M | 9.46M | 0.65M | 1.44M |
| Change to netincome | - | - | - | 16.82M | 16.14M |
| Capital expenditures | 1.03M | 1.68M | 1.99M | 2.68M | 3.47M |
| Change receivables | - | - | - | - | -4.93M |
| Cash flows other operating | - | - | - | - | 10.42M |
| Cash and cash equivalents changes | - | - | - | - | -8.73M |
| Change in working capital | -22.98M | -5.43M | -18.42M | -9.03M | -14.08M |
| Stock based compensation | 16.40M | 16.93M | 16.96M | 12.67M | 14.76M |
| Other non cash items | 8.42M | -5.81M | -4.83M | 4.62M | 2.12M |
| Free cash flow | 72.97M | 64.52M | 24.79M | -20.58M | -5.45M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group Inc |
-0.09 2.27% |
3.88 | 118.00 | 19.53 | 1.94 | 3.13 | 1.57 | 27.36 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
770 651 9100
808
| Name | Title | Year Born |
|---|---|---|
| Mr. K. Todd Newton | Interim CEO & Director | 1963 |
| Mr. Peter Martin Carlson CPA | Chief Financial Officer | 1964 |
| Mr. William F. Hulse IV | Gen. Counsel & Chief Admin. Officer | 1974 |
| Dr. Rohit Kashyap Ph.D. | Pres of Wound Care & Surgical | 1971 |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Pres of Regenerative Medicine & Biologics Innovation | 1951 |
| Mr. Scott M. Turner | Sr. VP of Operations & Procurement | 1965 |
| Mr. William L. Phelan | Sr. VP & Chief Accounting Officer | NA |
| Mr. Matthew M. Notarianni | Head of Investor Relations | NA |
| Mr. Mark P. Graves | Sr. VP & Chief Compliance Officer | 1966 |
| Hilary Dixon | VP of Investor Relations & Corp. Strategic Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...